These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3337860)

  • 21. Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery.
    Lang W; Masucci JA; Caldwell GW; Hageman W; Hall J; Jones WJ; Rafferty BM
    Anal Biochem; 2004 Oct; 333(1):79-87. PubMed ID: 15351283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.
    Baker GB; Coutts RT; McKenna KF; Sherry-McKenna RL
    J Psychiatry Neurosci; 1992 Nov; 17(5):206-14. PubMed ID: 1362653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution of biogenic amines and related enzymes in the rat pituitary gland.
    Saavedra JM; Palkovits M; Kizer JS; Brownstein M; Zivin JA
    J Neurochem; 1975 Sep; 25(3):257-60. PubMed ID: 240000
    [No Abstract]   [Full Text] [Related]  

  • 24. Age-related changes in brain biogenic monoamines and monoamine oxidase.
    Petkov VD; Stancheva SL; Petkov VV; Alova LG
    Gen Pharmacol; 1987; 18(4):397-401. PubMed ID: 3038666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.
    Green AR; Mitchell BD; Tordoff AF; Youdim MB
    Br J Pharmacol; 1977 Jul; 60(3):343-9. PubMed ID: 890205
    [No Abstract]   [Full Text] [Related]  

  • 26. Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake.
    Marley E; Wozniak KM
    J Psychiatr Res; 1984; 18(2):191-203. PubMed ID: 6235366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of amantadine on radiolabeled biogenic amines in the rat brain.
    Symchowicz S; Korduba CA; Veals J
    Eur J Pharmacol; 1973 Feb; 21(2):155-60. PubMed ID: 4696098
    [No Abstract]   [Full Text] [Related]  

  • 29. Urinary excretion of O-methylated catecholamines, tyramine and phenyl-ethylamine by volunteers treated with tranylcypromine and CGP 11305 A.
    Waldmeier PC; Antonin KH; Feldtrauer JJ; Grunenwald C; Paul E; Lauber J; Bieck P
    Eur J Clin Pharmacol; 1983; 25(3):361-8. PubMed ID: 6628524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of tryptamine in the behavioural changes caused by a monoamine oxidase inhibitor and L-tryptophan [proceedings].
    Curzon G; Marsden CA
    Br J Pharmacol; 1977 Jun; 60(2):307P-308P. PubMed ID: 880472
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of styrene oxide on levels of biogenic amines and activity of monoamine oxidase in different parts of rat brain.
    Husain R; Zaidi NF; Srivastava SP; Seth PK
    Bull Environ Contam Toxicol; 1985 May; 34(5):722-9. PubMed ID: 4005452
    [No Abstract]   [Full Text] [Related]  

  • 32. Enzymatic-isotopic micromethods for the measurement of biogenic amines in brain tissue and body fluids.
    Saavedra JM; Axelrod J
    J Psychiatr Res; 1974; 11():289-91. PubMed ID: 4618286
    [No Abstract]   [Full Text] [Related]  

  • 33. Ontogenesis of uptake and deamination of 5-hydroxytryptamine, dopamine and beta-phenylethylamine in isolated perfused lung and lung homogenates from rats.
    Ben-Harari RR; Youdim MB
    Br J Pharmacol; 1981 Apr; 72(4):731-7. PubMed ID: 7284689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoamine oxidase inhibition by tranylcypromine: assessment in human volunteers.
    Bieck PR; Antonin KH
    Eur J Clin Pharmacol; 1982; 22(4):301-8. PubMed ID: 7106165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect on [11C]DASB binding after tranylcypromine-induced increase in serotonin concentration: positron emission tomography studies in monkeys and rats.
    Lundquist P; Roman M; Syvänen S; Hartvig P; Blomquist G; Hammarlund-Udenaes M; Långström B
    Synapse; 2007 Jun; 61(6):440-9. PubMed ID: 17372973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of monoamine oxidase inhibitors on the tryptamine content of the rat brain and on "tryptamine convulsions"].
    Popov N; Lietz W; Matthies H
    Acta Biol Med Ger; 1967; 18(2):233-44. PubMed ID: 5586804
    [No Abstract]   [Full Text] [Related]  

  • 37. Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS.
    Lauber J; Waldmeier PC
    J Neural Transm; 1984; 60(3-4):247-64. PubMed ID: 6527139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase.
    Waldmeier PC; Baumann PA; Delini-Stula A; Bernasconi R; Sigg K; Buech O; Felner AE
    Mod Probl Pharmacopsychiatry; 1983; 19():31-52. PubMed ID: 6191211
    [No Abstract]   [Full Text] [Related]  

  • 39. Release of some endogenous trace amines from rat striatal slices in the presence and absence of a monoamine oxidase inhibitor.
    Dyck LE
    Life Sci; 1989; 44(17):1149-56. PubMed ID: 2716465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ontogenesis of enzyme systems deaminating different monoamines.
    Blatchford D; Holzbauer M
    Br J Pharmacol; 1976 Jun; 57(2):279-93. PubMed ID: 938797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.